The multiple roles of microRNA-155 in oncogenesis

Journal of Clinical Bioinformatics

Volumn 3, Issue 1, 2013, Pages

  Higgs, Gadareth ^a   Slack, Frank ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Anti miR therapy; miR 155; Nanoparticle delivery; Oncogenesis; OncomiRs

Indexed keywords

EID: 84896377503     PISSN: None     EISSN: 20439113     Source Type: Journal    
DOI: 10.1186/2043-9113-3-17     Document Type: Review

References (33)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233. 10.1016/j.cell.2009.01.002, 19167326.
2. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 2008, 9(2):102-114.
3. Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res 2012, 72(7):1751-1762. 10.1158/0008-5472.CAN-11-3027, 3319789, 22350414.
4. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochimica et biophysica acta 2009, 1792(6):497-505. 10.1016/j.bbadis.2009.02.013, 19268705.
5. Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. Yale J Biol Med 2006, 79(3-4):131-140. 1994807, 17940623.
6. Kala R, Peek GW, Hardy TM, Tollefsbol TO. MicroRNAs: an emerging science in cancer epigenetics. J Clin Bioinform 2013, 3(1):6.
7. Teng G, Papavasiliou FN. Shhh! Silencing by microRNA-155. Philos Transac Royal Soc Lond Series B 2009, 364(1517):631-637.
8. Sandhu SK, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G, Garzon R, et al. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. Proc Nat Acad Sci USA 2012, 109(49):20047-20052. 10.1073/pnas.1213764109, 3523868, 23169640.
9. Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, Ferracin M, Delmas D, Latruffe N, Croce CM. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogen 2010, 31(9):1561-1566.
10. Donnem T, Eklo K, Berg T, Sorbye SW, Lonvik K, Al-Saad S, Al-Shibli K, Andersen S, Stenvold H, Bremnes RM, et al. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Trans Med 2011, 9:6.
11. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009, 28(5):264-284. 10.1080/08830180903093796, 19811312.
12. Calame K. MicroRNA-155 function in B Cells. Immunity 2007, 27(6):825-827. 10.1016/j.immuni.2007.11.010, 18093533.
13. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et al. Regulation of the germinal center response by microRNA-155. Science 2007, 316(5824):604-608. 10.1126/science.1141229, 17463289.
14. Dagan LN, Jiang X, Bhatt S, Cubedo E, Rajewsky K, Lossos IS. miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood 2012, 119(2):513-520. 10.1182/blood-2011-08-370536, 3257016, 22096245.
15. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Nat Acad Sci USA 2012, 109(26):E1695-E1704. 10.1073/pnas.1201516109, 3387084, 22685206.
16. Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, Li B, Li Y, Li D, Wang ED, et al. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 2012, 31(8):1985-1998. 10.1038/emboj.2012.45, 3343331, 22354042.
17. Li S, Chen T, Zhong Z, Wang Y, Li Y, Zhao X. microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep 2012, 5(4):949-954. 3493052, 22307849.
18. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y, de Hoon MJ, Kubosaki A, Kaiho A, Suzuki M, et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010, 24(2):460-466. 10.1038/leu.2009.246, 19956200.
19. Willimott S, Wagner SD. miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem 2012, 287(4):2608-2617. 10.1074/jbc.M111.285718, 3268420, 22139839.
20. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, Haines DC, Basik M, Mai P, , et al. Kathleen Cuningham Foundation Consortium for Research into Familial Breast C Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nature Med 2011, 17(10):1275-1282. 10.1038/nm.2459, 3501198, 21946536, Kathleen Cuningham Foundation Consortium for Research into Familial Breast C.
21. Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, Rickert RC, Gronbaek K, David M. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med 2009, 1(5):288-295. 10.1002/emmm.200900028, 2771872,2771872, 19890474.
22. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR. Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 2010, 84(22):11670-11678. 10.1128/JVI.01248-10, 2977875, 20844043.
23. Huffaker TB, Hu R, Runtsch MC, Bake E, Chen X, Zhao J, Round JL, Baltimore D, O'Connell RM. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep 2012, 2(6):1697-1709. 10.1016/j.celrep.2012.10.025, 3628775, 23200854.
24. Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, Naldini L. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective anti-tumor responses. Blood 2013, 122(2):243-252. 10.1182/blood-2012-08-449306, 23487026.
25. Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenet 2010, 1(3-4):101-116.
26. Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. Epigenom 2011, 3(4):503-518.
27. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007, 67(9):4303-4310. 10.1158/0008-5472.CAN-06-4699, 17483343.
28. Zhang M, Zhou X, Wang B, Yung BC, Lee LJ, Ghoshal K, Lee RJ. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Cont Release 2013, 168(3):251-261.
29. Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunolog Rev 2013, 253(1):146-157.
30. Li Y, Liu L, Tollefsbol TO. Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression. FASEB J 2010, 24(5):1442-1453. 10.1096/fj.09-149328, 2996891, 20019239.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
32. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogen 2010, 31(1):37-49.
33. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121(11):2373-2380. 10.1002/ijc.23173, 17893866.